Challenges in Assessing the Cost-effectiveness of Cancer Immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. 1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL.Cells · 2026
   Article
2. Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials.Gynecologic oncology reports · 2026
   Article
3. Tumor immunology: unraveling the complex interaction between tumors and the immune system: a narrative review.Annals of medicine and surgery (2012) · 2025
   Review
4. Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients.European radiology · 2025
   Article
5. Breath- and blood-based molecular assessment for gastroesophageal cancer.ESMO gastrointestinal oncology · 2025
   Review
6. The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?Frontiers in immunology · 2025
   Review
7. Unlocking cancer vaccine potential: What are the key factors?Human vaccines & immunotherapeutics · 2024
   Review
8. The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancer.Exploration of targeted anti-tumor therapy · 2024
   Review
9. The Impact of Neighborhood Deprivation on the Survival Rates of Patients with Cancer in Korea.Healthcare (Basel, Switzerland) · 2023
   Article
10. Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment.Vaccines · 2023
    Review
11. Limitations of Immunotherapy in Cancer.Cureus · 2022
    Review
12. Hedgehog Suppresses Paclitaxel Sensitivity by Regulating Akt-Mediated Phosphorylation of Bax in EGFR Wild-Type Non-Small Cell Lung Cancer Cells.Frontiers in pharmacology · 2022
    Article
13. Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey.Cancer control : journal of the Moffitt Cancer Center
    Article

Corrections and comments

• Comment on
  Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.2021

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as